A comparison of transcatheter arterial chemoembolization used with and without apatinib for intermediate- to advanced-stage hepatocellular carcinoma: a systematic review and meta-analysis | Zendy

Shoujie Zhao | Zendy; Ting Zhang | Zendy; Weijia Dou | Zendy; E. Wang | Zendy; Mengmeng Wang | Zendy; Chengguo Wang | Zendy; Xilin Du | Zendy; Lei Liu | Zendy

Open Access

A comparison of transcatheter arterial chemoembolization used with and without apatinib for intermediate- to advanced-stage hepatocellular carcinoma: a systematic review and meta-analysis

Author(s) -

Shoujie Zhao,

Ting Zhang,

Weijia Dou,

E. Wang,

Mengmeng Wang,

Chengguo Wang,

Xilin Du,

Lei Liu

Publication year - 2020

Publication title -

annals of translational medicine

Language(s) - English

Resource type - Journals

eISSN - 2305-5847

pISSN - 2305-5839

DOI - 10.21037/atm.2020.02.125

Subject(s) - apatinib , medicine , hepatocellular carcinoma , meta analysis , cochrane library , oncology , publication bias , odds ratio , adverse effect , stage (stratigraphy) , survival rate , subgroup analysis , regimen , therapeutic effect , cancer , paleontology , biology

The combination treatment of apatinib and TACE provides better survival benefits for intermediate- to advanced-stage HCC patients when compared to TACE monotherapy and should be recommended for suitable patients with unresectable HCC. However, further investigation into future prospective clinical studies is warranted.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research